Antidepressant‐like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background and purpose: A crucial role for the GABA B receptor in depression was proposed several years ago, but there are limited data to support this proposition. Therefore we decided to investigate the antidepressant‐like activity of the selective GABA B receptor antagonists CGP 36742 and CGP 51176, and a selective agonist CGP 44532 in models of depression in rats and mice. Experimental approach: Effects of CGP 36742 and CGP 51176 as well as the agonist CGP 44532 were assessed in the forced swim test in mice. Both antagonists were also investigated in an olfactory bulbectomy (OB) model of depression in rats, while CGP 51176 was also investigated in the chronic mild stress (CMS) rat model of depression. The density of GABA B receptors in the mouse hippocampus after chronic administration of CGP 51176 was also investigated. Key results: The GABA B receptor antagonists CGP 36742 and CGP 51176 exhibited antidepressant‐like activity in the forced swim test in mice. The GABA B receptor agonist CGP 44532 was not effective in this test, however, it counteracted the antidepressant‐like effects of CGP 51176. The antagonists CGP 36742 and CGP 51176 were effective in an OB model of depression in rats. CGP 51176 was also effective in the CMS rat model of depression. Administration of CGP 51176 increased the density of GABA B receptors in the mouse hippocampus. Conclusions and Implications: These data suggest that selective GABA B receptor antagonists may be useful in treatment of depression, and support an important role for GABA‐ergic transmission in this disorder. British Journal of Pharmacology (2006) 149, 581–590. doi:10.1038/sj.bjp.0706845
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Behavioural despair in rats: A new model sensitive to antidepressant treatments
Porsolt, R. D., Anton, G., Blavet, N., & Jalfre, M. (1978) · European Journal of Pharmacology · doi:10.1016/0014-2999(78)90118-8 · Cited by 3,138
Willner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832 · cited 2×
“Moreover, as in most of the previous studies with the CMS model (Willner, 1997, 2005), we observed that the action of imipramine had several parallels with its clinical activity, in terms of its efficacy (full recovery at the end treatment period), specificity (as indicated by a lack of significant…”
BackgroundResultWillner, P. (2005) · Neuropsychobiology · doi:10.1159/000087097 · Cited by 1,605 · cited 2×
“Moreover, as in most of the previous studies with the CMS model (Willner, 1997, 2005), we observed that the action of imipramine had several parallels with its clinical activity, in terms of its efficacy (full recovery at the end treatment period), specificity (as indicated by a lack of significant…”
BackgroundResultSanacora, G., Mason, G. F., Rothman, D. L., Behar, K. L., Hyder, F., Petroff, O. A. C., Berman, R. M., Charney, D. S., & Krystal, J. H. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.11.1043 · Cited by 627 · cited 1×
“Using proton magnetic resonance spectroscopy, lowered GABA levels were detected in depressed patients (Sanacora et al., 1999, 2004), which were normalized after administration of electroconvulsive treatment (Sanacora et al., 2002) or antidepressant drugs (Sanacora et al., 2002; Bhagwagar et al.,…”
BackgroundThe ABC of GABA receptors: a brief review
Chebib, M., & Johnston, G. A. R. (1999) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.1999.03151.x · Cited by 436 · cited 1×
“GABA is the major inhibitory neurotransmitter in the central nervous system (Paredes and Agmo, 1992), acting via stimulation of GABAA, GABAB and GABAC receptors (Chebib and Johnston, 1999; Bormann, 2000; Rudolph et al., 2001).”
BackgroundPharmacological validation of the chronic mild stress model of depression
Papp, M., Moryl, E., & Willner, P. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00697-4 · Cited by 205
Self-citationLuján, R., Shigemoto, R., Kulik, A., & Juiz, J. M. (2004) · Journal of Comparative Neurology · doi:10.1002/cne.20160 · Cited by 51 · cited 1×
“On the subcellular level, most GABAB receptors are extrasynaptic, sometimes localized in close proximity to glutamatergic synapses (Fritschy et al., 1999; Lujan et al., 2004).”
Background
Cited by
Antoniuk, S., Bijata, M., Ponimaskin, E., & Wlodarczyk, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.12.002 · Cited by 750
Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions
Fogaça, M. V., & Duman, R. S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00087 · Cited by 396
Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression
Karolewicz, B., Maciag, D., O'Dwyer, G., Stockmeier, C. A., Feyissa, A. M., & Rajkowska, G. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990587 · Cited by 203
Pham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
“A chronic pharmacological blockade of GABAB-Rs increases adult hippocampal neurogenesis and induced an antidepressant-like response in BALB/Cj mice (Felice, O'Leary, Pizzo, & Cryan, 2012; Mombereau et al., 2004; Nowak et al., 2006).”
BackgroundKumar, K., Sharma, S., Kumar, P., & Deshmukh, R. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.07.003 · Cited by 125
Metadata
- Authors
- Nowak, G., Partyka, A., Pałucha, A., Szewczyk, B., Wierońska, J. M., Dybała, M., Metz, M., Librowski, T., Froestl, W., Papp, M., & Pilc, A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2006-11
- Volume
- 149
- Issue
- 5
- Pages
- 581-590
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2011938658
- Cited by
- 69
- References
- 7
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.